-
JIANBO WEI
Partner·Beijing
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MR. JIANBO WEI SPECIALIZES IN OVERSEAS CAPITAL MARKETS, M&A, PRIVATE EQUITY INVESTMENT, FOREIGN DIRECT INVESTMENT AND GENERAL CORPORATE.
Education
Renmin University of China, Master of Laws
China Foreign Affairs University, Bachelor of Laws
China Foreign Affairs University, B.A. in English Literature
Professional Qualification
Admitted to practice in the PRC
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Represented Kingsoft Cloud Holdings Limited (NASDAQ: KC) in its initial public offering on the NASDAQ
- Represented Qudian Inc. (NYSE: QD) in its initial public offering on the New York Stock Exchange
- Represented Jianpu Technology Inc. (Rong360) (NYSE: JT) in its initial public offering on the New York Stock Exchange
- Represented Cango Inc. (NYSE: CANG) in its initial public offering on the New York Stock Exchange
- Represented the underwriters Morgan Stanley, Credit Suisse, and Citigroup in connection with the initial public offering of Huami Corporation (NYSE: HMI) on the New York Stock Exchange
- Represented the underwriters Citigroup, Deutsche Bank Securities, AMTD, China Merchants Securities (HK), and Tiger Brokers in connection with the initial public offering of UP Fintech Holding Limited (NASDAQ: TIGR) on the NASDAQ
- Represented the underwriters Morgan Stanley and J.P. Morgan in the Kingsoft Corporation Limited (HK: 3888) issuance of HK$3.1 billion in convertible bonds due 2025
- Represented Warburg Pincus in its strategic investment in Ant Financial
- Represented Warburg Pincus in its strategic investment in Henan Zhongyuan Consumer Finance Co., Ltd
- Represented CITIC PE in its strategic investment in JD Health International Inc
- Represented Junzheng Group in its purchase of a 15.3% stake of Huatai Insurance
- Represented Canada Scotiabank in its strategic investment in the Bank of Xi’an
- Represented Alibaba in its strategic investment in Enlight Media
- Represented Didi Chuxing in its strategic investment in Ren Ren Che
- Represented Primavera Capital in its investment in Souche
- Represented Kuaishou in its Series E financing
- Represented Foshan Deruike Pharmaceuticals Co., Ltd in receiving investment from Hainan Sihuan Pharmaceutical Co., Ltd. of up to RMB 400 million
- Represented Haisco Pharmaceutical Group Co., Ltd, an A-share listed company, in its investment in Israeli medical device enterprises, including MST Medical Surgery Technologies Ltd., Sensible Medical Innovations Ltd., Endospan Ltd., and Newpace Ltd
- Represented Jumei in its investment in Jiedian
- Acted as legal advisor on general corporate affairs for listed companies including Sina, Jianpu (Rong360), Qudian, Jumei, and Cango
